Get the Stockscreener App
0.7399
0.09%
0.00065
After Hours:
.74
0.000100
+0.01%
Aptorum Group Ltd stock is traded at $0.7399, with a volume of 25,720.
It is up +0.09% in the last 24 hours and up +0.53% over the past month.
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
See More
Previous Close:
$0.7393
Open:
$0.7395
24h Volume:
25,720
Relative Volume:
0.64
Market Cap:
$4.15M
Revenue:
$1.20M
Net Income/Loss:
$-2.82M
P/E Ratio:
-0.2724
EPS:
-2.7164
Net Cash Flow:
$-7.73M
1W Performance:
-3.50%
1M Performance:
+0.53%
6M Performance:
-83.74%
1Y Performance:
-63.19%
1-Day Range:
$0.71
$0.7665
1-Week Range:
$0.672
$0.7819
52-Week Range:
$0.46
$17.49
Aptorum Group Ltd Stock (APM) Company Profile
Compare APM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APM
Aptorum Group Ltd
|
0.7399 | 4.15M | 1.20M | -2.82M | -7.73M | -0.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Aptorum Group Ltd Stock (APM) Latest News
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024 - sharewise
Aptorum Group Narrows Losses by 59% in H1 2024, Terminates Yoov Merger Amid Market Challenges - StockTitan
Why Credo Technology Group Shares Are Trading Higher By 40%; Here Are 20 Stocks Moving Premarket - Benzinga
Aptorum Group Stock Hits 52-Week Low at $1.2 Amid Market Challenges - Investing.com India
Aptorum Group announces annual shareholder meeting details By Investing.com - Investing.com Australia
Aptorum Group announces annual shareholder meeting details - Investing.com India
Aptorum stock hits 52-week low at $1.34 amid market challenges - Investing.com India
Oil prices soar after OPEC+ delays production hike - Investing.com
Andean Precious Metals (CVE:APM) Upgraded at Desjardins - Defense World
Aptorum Group stock hits 52-week low at $1.35 amid market challenges - Investing.com Australia
Aptorum Group to Hold Investor Webinar and Present at The Wall Street Investor Forum on September 10 - AsiaOne
Andean Precious Metals (CVE:APM) Reaches New 1-Year High Following Insider Buying Activity - MarketBeat
Oncology And Infectious Diseases Focused Aptorum Stock Skyrockets 7X On WednesdayHere's Why - MSN
Aptorum Group Limited (NASDAQ:APM) Sees Large Growth in Short Interest - Defense World
Aptorum Group Limited (NASDAQ:APM) Short Interest Down 47.1% in July - Defense World
Aptorum Group Limited (NASDAQ:APM) Short Interest Update - Defense World
NASDAQ – Stock Price, Charts & News Today - BNN Bloomberg
Aptorum Group (NASDAQ:APM) Trading Up 0.4% - Defense World
Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session - Benzinga
symbol__ Stock Quote Price and Forecast - CNN
US Stocks Higher; Producer Prices Rise 0.6% In February - Benzinga
Nasdaq Rises 100 Points; BJ's Wholesale Posts Weak Sales - Benzinga
Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a ... - sharewise
Aptorum and YOOV announce merger plan - Investing.com
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023 - Business Wire
Aptorum Group Limited Announces Resignation of Thomas Lee as Head of Research and Development - Marketscreener.com
Why Is Aptorum (APM) Stock Down 16% Today? - InvestorPlace
Menopause Market Size, Share And Trends Report, 2031 - SkyQuest Technology
Cotações de Ações Americanas (STOCKS) - Money Times
DelveInsight Estimates a Promising Picture of Obesity Pipeline Space Landscape as Key 100+ Pharma Companies Working in the Space - PR Newswire
Aptorum Group Updates on the Clinical Validation of RPIDD Infectious Disease Liquid Biopsy Molecular Diagnostics - ACROFAN
Notice to Boustead Securities Customers Who Purchased IPOs - GlobeNewswire
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 2, 2021 - Business Wire
Aptorum GroupAPMHigh RIsk Biotech Stocks Buy, Sell, Hold Investing Analysis for the Long-run - The Market Oracle
Aptorum Gr (NASDAQ:APM) Stock Quotes, Forecast and News Summary - Benzinga
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study - Markets Insider
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 9, 2020 - businesswire.com
Aptorum Group Limited (NASDAQ:APM) Unveils Infectious Disease Liquid Biopsy Subsidiary to Co-develop RPIDD Tech - BP Journal
Aptorum Soars 800% On Diagnostic Testing Launch - Benzinga
Aptorum Group Ltd (NASDAQ:APM) Pleased To Unveil Video Indicating Positive Results On SACT-1 - BP Journal
Aptorum Group Announces Further Positive Data on ALS-4 against MRSA Wound Infection and MRSA Bacteraemia against Linezolid and Vancomycin Respectively in In Vivo Models - Business Wire
Yam for maam: Aptorum Group to launch women’s bone health supplement made from Chinese yam - NutraIngredients-Asia
Aptorum Group Announces Significant Progress of Repurposed Drug Candidate, SACT-1 for Neuroblastoma Targeting IND Submission in H2 2020 - AsiaOne
Aeneas Capital and Pyrinas Target Launch of US$120m Fund to Develop Co-Working Laboratory Ecosystems for Life Sciences Start-Ups in the United States - BioSpace
Argus Research Initiates Equity Research Report Coverage on Aptorum Group Limited (NasdaqGM: APM) - GlobeNewswire
Hong Kong pharma start-up joins Singapore technology agency in venture fund - South China Morning Post
USD$90 million initiative between A*Star, Aptorum Group and Aeneas Capital to drive healthcare innovations - Agency for Science, Technology and Research (A*STAR)
Aptorum Group (APM) Stock Price, News & Analysis - MarketBeat
APM Stock Price and Chart — NASDAQ:APM - TradingView
Is biotech in Hong Kong doomed to fail, despite the sector’s potential? - South China Morning Post
Aptorum Group Ltd Stock (APM) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):